1 Parkin D M, Bray F, Ferlay J, et al. Estimating the world cancer burden:Globocan 2000. Int J Cancer, 2001, 94: 153-156？？
[2]
2 Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol, 2006, 12: 1175-1181
[3]
3 Taketa K. a-fetoprotein: revaluation in hepatology. Hepatology, 1990, 12: 1420-1432？？
[4]
4 Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest, 2001, 108: 497-501
[5]
5 Zhu Z W, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001, 48: 558-564？？
[6]
6 Zhou X P, Wang H Y, Yang G S,et al. Cloning and expression of MXR7 gene in human HCC tissue. World J Gastroenterol, 2000, 6: 57-60
[7]
7 Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res, 2004, 64: 2418-2423？？
[8]
8 Zhang QY, Qin X, Zhen L,et al. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem, 2010, 43: 1003-1008？？
[9]
9 El-Shenawy S Z, Sabawi M M E1, Sheble N, et al. Diagnostic role of serum glypican-3 as a tumor marker for hepatocellular carcinoma. Nat Sci, 2012, 10: 32-38
[10]
10 Wang F H, Yip Y C, Zhang M, et al. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. J Clin Pathol, 2010, 63: 599-603？？
[11]
11 Mariana C, Ian R W, Morris S, et al. Glypican-3 a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology, 2003, 125: 89-97？？
[12]
12 Llovet J M, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology, 2006, 131: 1758-1767？？
[13]
13 Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis, 2010, 30: 017-025？？
[14]
14 Bruix J, Morris S. Management of hepatocellular carcinoma: an update. Hepatology, 2011, 53: 1020-1022？？
[15]
15 Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001, 48: 558-564？？
[16]
16 Yutaka M, Shumpei I, Hiroko I, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer, 2003, 103: 455-465
[17]
17 Wang X Y, Degos F, Dubois S, et al. Glypican-3 expression in Hepatocellular tumors:diagnostic value for preneoplastic lesions and Hepatocellular carcinomas. Hum Pathol, 2006, 37: 1435-1441？？
[18]
18 Liu H, Li P, Zhai Y, et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol, 2010, 16: 4410-4415？？
[19]
19 Soha ZE1-S, Maha ME1 S, Nashwa S, et al. Diagnostic role of serum glypican-3 as a tumor marker for hepatocellular carcinoma. Nat Sci, 2012, 10: 32-38
